Funding to advance a breakthrough non-hormonal treatment for symptoms of the menopause, into a Phase 2b study in Q4 2018

Stevenage, UK, 29 August 2018 – KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a Series C financing round, raising £25 million from new US investor Longitude Capital, and existing internationally recognised life sciences investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.

The proceeds will enable KaNDy Therapeutics to advance its breakthrough non-hormonal drug candidate, NT-814, for treatment of multiple symptoms of the menopause, through a multi-country Phase 2b dose-ranging study due to start recruiting patients in Q4 2018 with headline results expected in late 2019.

Commenting on the financing round, Mary Kerr CEO of KaNDy Therapeutics, said:”We are delighted by the level of enthusiasm and financial support we have received from our investors and would like to welcome Longitude Capital into the syndicate and the board of directors. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide who suffer debilitating symptoms of the menopause.”

NT-814 is an orally administered once daily, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors. It is being developed by KaNDy Therapeutics to provide a viable alternative to hormone replacement therapy. In June 2018, the Company announced positive data from the Phase Ib/IIa proof of concept clinical trial which showed that women who were treated with NT-814 once daily for two weeks at the most effective doses evaluated, experienced a rapid and profound reduction in two key symptoms of the menopause, namely frequency and severity of hot flashes and the number of night time awakenings

Josh Richardson, M.D., Managing Director of Longitude Capital said: “We were very pleased to participate in this funding round. We have been impressed with the data announced thus far, by KaNDy’s business strategy and the strong and experienced management team. We believe NT-814 has the potential to greatly improve the quality of life of millions of women worldwide and we look forward to supporting the Company as it continues to progress this potentially transformational candidate through the clinic towards commercialization.”

A Phase 2b study to further evaluate the safety and efficacy of NT-814 in women with bothersome post-menopausal symptoms, and to establish the optimum dose to take forward into Phase 3, is anticipated to start recruiting patients in the US, Canada and the UK in Q4 2018, with headline results expected in late 2019.

International private equity firm, Cinven, today announces that it has successfully completed the final sell down of its remaining shares in Nasdaq-listed Medpace (‘the Group’), a leading contract research organisation (‘CRO’). Following this transaction, Medpace becomes a fully realised investment for Cinven, generating highly successful returns for the Fifth Cinven Fund.

Headquartered in Cincinnati, Ohio, Medpace is a global CRO operator providing management services to the R&D departments of pharma, biotech and medical device clients to help plan and oversee their clinical trials. Medpace focuses on small to mid-size companies and has significant expertise in numerous therapeutic areas, operating across 36 countries worldwide.

Cinven’s Healthcare team identified the CRO industry as an attractive market in which to invest. Following its detailed sector review work, Cinven acquired Medpace in February 2014 for a total consideration of US$915 million.

During Cinven’s ownership of Medpace, strong progress was made by Medpace’s industry-leading management team across a number of key pillars of Cinven’s investment thesis:

• International expansion: Medpace continued to expand significantly outside of the US including in Europe and Asia;
• New therapeutic areas: Medpace successfully developed its therapeutic franchises including anti-viral/anti-infective and oncology, and consolidated its position in existing therapeutic areas, such as metabolic and cardiovascular, as well as later-stage trials; and
• Investment-led growth: Significant investment was made into Medpace’s human capital and infrastructure to position the Group for further growth. In particular, Cinven enabled the senior management to make the strategic hires necessary to grow the business. Medpace’s workforce increased by more than 55% during Cinven’s investment, with the number of employees growing from approx. 1,500 in 2014 to 2,700 today.

As a result, Medpace delivered strong financial performance under Cinven’s ownership, driven by trading growth momentum, industry-leading margins and strong cash conversion.

On the back of this strong performance, in August 2016, Medpace achieved a highly successful all-primary IPO on the Nasdaq Global Select Market at US$23 per share. Medpace’s share price has performed well in the aftermarket, and Cinven has monetised its investment in Medpace through a series of sell downs, culminating in the final sell down on 22 August 2018 at a c.138% premium to the IPO price.

Commenting on the transaction, Alex Leslie, Partner in Cinven’s New York office, said:

“Cinven’s investment in Medpace stemmed from a high conviction thesis that we developed within Cinven’s Healthcare Team, which anticipated strong growth in the CRO industry fuelled by increased R&D spending by the pharma industry and the growing complexity and number of clinical trials required to bring new molecules to market.

“We expected this would be especially pronounced in the smaller pharma and biotech segments of the market, where Medpace focuses. This thesis has played out and has resulted in Medpace delivering an excellent returns.”

John Richardson, Senior Principal in Cinven’s New York office, added:

“Cinven backed a strong management team at Medpace, led by CEO, Dr August Troendle, and invested significantly in his team and the Group’s infrastructure, including IT systems and clinical operations. Medpace is a strong example of Cinven’s successful sector / regional approach – how the Cinven Healthcare and US teams have worked closely together to grow a business and generate highly attractive returns for Cinven’s investors.”

The transaction is expected to close on or around 27 August 2018 subject to customary closing conditions.

The final realisation of Medpace follows Cinven’s recent successful exits of CeramTec, CPA Global, Viridium Group and Ufinet Group.

c-LEcta, a world-leading biotechnology company focused on enzyme engineering and applications in regulated markets like food and pharma, has closed a financing round with Capricorn Venture Partners and the German investment company bm|t. The capital increase provides the company with growth capital as well as valuable access to an international network.

c-LEcta already has a diversified shareholder structure. In addition to the founder, Dr. Marc Struhalla, private industrial investors and German institutionals, the company has now expanded its circle of shareholders by attracting international investors. c-LEcta has received growth capital from two new shareholders. Lead investor, Capricorn Venture Partners, is an independent, internationally oriented investment company, based in Leuven, Belgium. Capricorn invests in innovative, technology driven companies and has a multidisciplinary team of experienced investment professionals. Capricorn invested through two funds, namely the Capricorn Sustainable Chemistry Fund NV and Quest for Growth NV. The German investment company bm|t invests in high-growth technology companies led by entrepreneurial teams. bm|t invested via the MFT Mittelstands-Fonds Thüringen GmbH & Co. KG. These new funds are planned to be particularly invested in the approval, launch and scale-up of products from the project pipeline, further development of the pipeline as well as the expansion of international sales.

Mr. Ludwig Goris, Investment Manager of Capricorn, commented on the investment in c-LEcta: “We see that global mega trends and challenges in human nutrition are paving the way for industrial biotech companies like c-LEcta. Since its foundation, c-LEcta has built up a remarkable track record of technology and product development and has been able to validate that through a growing customer base of leading pharma, chemical and food ingredient companies. In addition, we were impressed by the highly qualified team in Leipzig. Founder and CEO Dr. Marc Struhalla and his motivated team have created a great company that has arrived at an attractive inflection point where the current product pipeline forms the foundation for an accelerated growth curve. We are proud to lead this growth capital round and contribute to the success of c-LEcta.”

Kevin Reeder, CEO of bm|t added, “bm|t, which has a substantial life sciences portfolio, is very optimistic about its investment in c-LEcta. The company´s strong team, track record of successful development, and a highly compelling product pipeline were extremely impressive. We feel c-LEcta is well-positioned to transition to a high-value biotechnology product company.” The two new investors expand the group of shareholders, which previously included the following investors: SHS Gesellschaft für Beteiligungsmanagement mbH, High-Tech Gründerfonds Management GmbH, KfW Bankengruppe, Dr. Marc Struhalla, Warning Beteiligungs GmbH, Dr. Bader Beteiligungs GmbH, and Arthur Steinmetz Beteiligungs GmbH.

In order to reinforce management and the board and support the anticipated growth, Thomas Pfaadt (45) recently joined c-LEcta as CFO. He enriches the company with his experience in corporate finance and M&A. Previously Thomas Pfaadt worked for a private equity-owned operator of rehabilitation clinics as well as for a family-owned integrated healthcare group. He also gained experiences as an investment banker and consultant with a strong focus on the healthcare sector. He commented on what excites him about c-LEcta: “c-LEcta is a young, lean, and dynamic company and a global player at the same time. We are fighting the serious challenges of today’s human nutrition. A growing population and a growing demand for healthy natural food require solutions from enzyme technologies that the chemical industry cannot provide. We are pleased to have won these two new investors to finance our work in addressing these large opportunities.”

c-LEcta is a fully integrated biotechnology company based in Leipzig, Germany, with focus on enzyme engineering and application in regulated markets like food and pharma. c-LEcta currently employs around 60 people. The company is well diversified and covers a large part of the value chain from discovery to engineering to the commercial production of enzymes as well as the manufacturing of other high-quality biotechnology products, either as in-house developments or in close coöperation with the industry. Over the last five years, c-LEcta has conducted more than 30 enzyme engineering projects with a success rate of >90%. Only a few weeks ago, the company announced a major breakthrough as the first company to develop a process to enable the mass-production of a plant-based sweetener with a real sugar-like taste. In addition, two further food ingredient products with high market potential are in an advanced development stage and the project pipeline comprises several promising candidates addressing the multi-billion-euro food ingredients market. This growth financing is intended to raise c-LEcta to a new level and elevate the focused food ingredients from the project pipeline to commercial scale production.

CEO Dr. Marc Struhalla commented on c-LEcta’s core technology and the capital increase: «The performance requirements for enzymes to be applied in industrial processes are in most cases very specific and vary from naturally occurring variations. Enzymes therefore need to be adapted to industrial conditions via enzyme engineering, and c-LEcta owns one of the most efficient technology platforms in this area. For enzyme optimization as well as for the development of artificial enzyme activities, we use patent-protected strategies that are inspired by nature. The industrial application of these technologies holds great market potential. The financial strength and valuable international network that we have gained through this financing round now offers us the opportunity to develop the full potential of our technology and people. With Capricorn Venture Partners and bm|t, we get two active investors on board that can contribute substantially to our international growth ambitions. Also, I am all the more pleased that our new CFOThomas Pfaadt will support us in this endeavor. Our goal is that in the future c-LEcta´s technology will be employed in many things we encounter in everyday life.”

About Capricorn Venture Partners:

Capricorn Venture Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as competitive advantage. It is based in Leuven, Belgium and licensed by the FSMA (the Financial Services and Markets Authority in Belgium).

About bm|t:

Erfurt-based, bm|t beteiligungsmanagement thüringen gmbh (bm|t) is the largest growth investor in the federal state of Thuringia, Germany. bm-t invests in innovative companies with strong growth potential across all sectors and phases of the corporate lifecycle.

About c-LEcta

c-LEcta is a fully integrated world-leading biotechnology company with focus on enzyme engineering and application in regulated markets like food and pharma. The company is located in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close coöperation with industry. The company currently employs around 60 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than 10 successfully commercialized high-value industrial biotech products.

Carlyle’s Global Platform and Deep Industry Expertise To Help Grow and Scale the Business

New York, NY – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that it is making a significant minority investment of up to $350 million into 1Life Healthcare, the technology and management company behind One Medical, to support the company’s growth. One Medical is the largest independently held primary care practice in the U.S. The company is working to transform health care by making high-quality primary care personal, accessible and affordable.

One Medical CEO Amir Dan Rubin said, “Partnering with Carlyle, given their extensive network and significant resources, will fuel our next stage of growth and innovation. Carlyle has a deep understanding of the health care sector and a track record of helping to build market-leading companies, while maintaining the highest levels of quality and patient support.”

Ram Jagannath, Managing Director on Carlyle’s Healthcare team, said, “We are excited to partner with Amir Dan Rubin and the One Medical team to continue growing and building out the platform. The company has developed an innovative, membership-based model that key stakeholders — including patients, providers, employers and health systems — find highly compelling. One Medical’s combination of best-in-class service and seamlessly integrated technology is delighting patients in an increasingly frustrating primary care environment. We look forward to working with the company to bring the One Medical brand and experience to more patients across the country.”

Founded in 2007, One Medical is reimagining primary care by improving the quality, service and affordability of care through a technology-enabled model. The company provides service in nine metropolitan regions: Boston, Chicago, Los Angeles, New York, Phoenix, San Francisco, Seattle, San Diego and Washington, DC. In addition to its consumer membership model, more than 1,000 companies have added One Medical to their health benefits packages, giving employees unparalleled, integrated access to near-site primary care, 24/7 virtual care and even on-site care that helps them improve population health and decrease overall health care costs. Health systems are now also partnering with One Medical as they acknowledge the value of having high-quality longitudinal, preventative care in their networks.

Bruce Dunlevie, Partner at Benchmark Capital and current 1Life Healthcare board member, said, “We are excited to have Carlyle join the 1Life Healthcare Board and investor group to help advance One Medical’s mission to transform health care. The primary proceeds from Carlyle’s investment will help fund One Medical’s go-forward expansion, while the Carlyle team’s experience building successful health care companies will serve as a valuable asset for the company.”

Equity for the transaction comes from Carlyle Partners VII, an $18.5 billion fund that makes majority and strategic minority investments primarily in the U.S. across five industries. The investment in One Medical is a continuation of Carlyle’s long-term global commitment to health care, in which it has invested more than $11 billion of equity since inception. Carlyle’s significant experience investing in the healthcare space includes MedRisk, Albany Molecular Research, PPD, WellDyneRx, Ortho Clinical Diagnostics, Rede D’Or São Luiz, Healthscope, Qualicorp, MultiPlan, and most recently, Millicent Pharma.

Latham & Watkins LLP served as legal advisor to Carlyle.

* * * * *

About One Medical

One Medical is the nation’s leading member-based, technology-powered national primary care organization focused on transforming health care. One Medical delivers it unique model of real life care through digital health services and convenient medical offices in 72 locations in nine metropolitan regions, including Boston, Chicago, Los Angeles, New York, Phoenix, San Francisco, Seattle,  Washington, D.C, and San Diego (launching next year).

In addition to its direct-to-consumer membership model, One Medical works with more than 1,000 companies who have added One Medical to their health benefits packages, giving their employees unparalleled, integrated access to near-site primary care, 24/7 virtual care, and even on-site care that helps them improve population health and decrease health care costs. One Medical is affiliated with 1Life Healthcare, Inc., a healthcare technology and management services company.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $210 billion of assets under management across 335 investment vehicles as of June 30, 2018. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Credit and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,625 people in 31 offices across six continents.

Web: www.carlyle.com
Videos: www.youtube.com/onecarlyle
Tweets: www.twitter.com/onecarlyle
Podcasts: www.carlyle.com/about-carlyle/market-commentary

Contact:
Chris Ullman
+1 (202) 729-5450
Chris.ullman@carlyle.com

3i Group plc (“3i”) today announces that Ponroy Santé Group (“Ponroy”), a leading European company in the natural consumer healthcare industry in which 3i invested in January 2017 together with co-investor Cathay Capital, is acquiring Densmore, a natural food supplement laboratory mainly specialising in ophthalmic solutions to treat eye diseases.

Densmore was founded in 1946 and is headquartered in Monaco. Its main brand, Suveal Duo, is a medically-proven supplement designed to fight age-related macular degeneration (“AMD”), a noncurable chronic disease affecting patients’ vision. Densmore has a 17% market share in this category and its products are regarded as being amongst the most innovative in the market. In addition to Suveal Duo, Densmore offers a range of complementary products for conditions such as glaucoma (Memoptic), inflammation and dry eyes. Its products are prescribed to patients directly by ophthalmologists. Densmore has enjoyed 17% p.a. organic sales growth since 2007 and is expected to generate close to €13m of sales in 2018. Its acquisition adds a new product line to Ponroy’s offering in the pharmacy channel and will also enhance Ponroy’s female care offering through other products including gynaecological food supplements. The CEO of Densmore, Philippe Caron, will join Ponroy and continue to lead the business.

This is the second acquisition made by Ponroy with the support of 3i. In September 2017, it acquired Ersa (Aragan and Synactifs brands), a designer and distributor of premium pharmaceutical food supplements, which strengthened its presence in the pharmacy channel and in the probiotic segment. Thanks to these acquisitions, Ponroy is now the third largest player in the French food supplement pharmacy channel, and aims to replicate its successful business model in other major geographies offering significant growth potential.

Philippe Charrier, President and CEO of Ponroy, commented:

“Densmore is an innovative and fast growing company, and a great fit for Ponroy. Its natural products are backed by strong medical studies, reinforcing Ponroy’s own medical credibility. We look forward to working with Philippe Caron and his team.”

Nicolas Brodetsky, Vice President of Ponroy and Group Head of Pharmacy, added:

“Phillippe Caron is an entrepreneur and we share the same values. Beyond the already strong products, Densmore has a rich pipeline of innovation complementary to ours that Ponroy can bring to market not only in France but also through our international network of partners and subsidiaries.”

Rémi Carnimolla, Partner and Managing Director, 3i France, and Guillaume Basquin, Director, 3i France commented:

“This is an important strategic acquisition for Ponroy and fully in line with 3i’s buy-and-build strategy of helping its portfolio companies to expand. Densmore is an R&D-oriented business with an exciting innovation pipeline and has demonstrated strong financial performance over the last 10 years.” 

For further information, contact:
3i Group plc

The family investment holding company, DENTRESSANGLE has announced that it is in exclusive discussions with BRIDGEPOINT DEVELOPMENT CAPITAL (BDC), the SMid-Cap business of BRIDGEPOINT, to acquire a majority stake in ACTEON Group, a French medtech company specialized in high-technology dental and medical equipment.

Over $100 million raised to progress its pipeline of next-generation oncolytic immunotherapies

Company has progressed from seed financing to IPO in three years

Forbion, a leading European life science venture capital firm, today announces that its portfolio company Replimune Group, Inc. (‘Replimune’) has successful completed an initial public offering (IPO) on NASDAQ, raising over $100 million for the development of its next-generation oncolytic immunotherapies. Replimune’s stock has started trading under the ticker symbol “REPL”.

Forbion has been a longstanding supporter of Replimune’s growth and development having invested seed capital three years ago at the time of the Company’s formation. Forbion identified the potential of Replimune following its investment in BioVex Inc. and knowledge and experience of oncolytic immunotherapy. BioVex was sold to Amgen in 2011 for up to US$1 billion which delivered a significant return for Forbion. Replimune’s co-founder and current Executive Chairman Philip Astley-Sparke was the President and CEO of BioVex Inc. and is now a Venture Partner at Forbion.

Replimune is developing oncolytic immunotherapies intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ technology platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment.
Commenting, Sander Slootweg, Managing Partner, said:

“We are proud to have been integrally involved in Replimune’s creation and to have nurtured its growth and development over the last three years. This successful IPO and fundraising only three years after we invested seed capital recognizes the potential of the company, its technology and pipeline and will help progress the development of its next generation oncolytic immunotherapies.”

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. Forbion invests in life sciences companies that are active in the pharmaceutical, as well as the medical device space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 50 companies. Forbion manages well over EUR 1 billion across ten funds. Its investors include the EIF, through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities and the KFW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion also operates a joint venture with BGV, the manager of seed and early stage funds focused on Benelux and Germany. www.forbion.com

Contacts

Forbion contact:
Sander Slootweg
Managing Partner
P: +31 (0) 35 699 30 00
E: sander.slootweg@forbion.com

Media contact:
Instinctif Partners (on behalf of Forbion)
Ashley Tapp/Ambrose Fullalove
P: +44 (0) 20 7457 2020
E: forbion@instinctif.com

Combined organization will bring together complementary strengths with a shared focus on accelerated customer value through patient-centric clinical technology solutions

London, United Kingdom and Wayne, Pennsylvania, USA (July 17, 2018) – Genstar Capital, a leading investor in healthcare technology and services companies, is pleased to announce the acquisition of CRF Health, a global provider of eCOA and eConsent solutions for the life sciences industry. As part of the transaction, CRF will be combined with Bracket, a provider of software and technology-enabled solutions utilized in clinical trials. Bracket is a portfolio company of Genstar.

CRF Health has been majority-owned by Vitruvian Partners, a leading growth-and technology-focused investment firm, since 2015.

The newly combined organization will drive accelerated value for pharmaceutical companies and CRO customers, providing patient-centric solutions, combined with deep and broad therapeutic area expertise, across a strong and efficient global footprint.

“CRF Health earned an outstanding reputation with 20 years of experience providing eCOA and now eConsent solutions to the biopharma industry around the world,” said Mike Nolte, who will lead the combined organization as CEO. “CRF’s technology and therapeutic experience dovetail well with our solutions, and they expand our ability to support increasingly complex clinical research. I am excited to bring two outstanding teams together to provide a reliable and scalable platform that accelerates the development of life changing medicines for our families and communities across the globe.”

The combined company will have over 1,500 employees worldwide, and will be in a position to accelerate the penetration of user-friendly technologies across the clinical trial spectrum – driving the transfer from manual, paper based services to electronic while improving service quality and data integrity.

“This is an exciting step forward for patients, clients, and our new combined team,” said Rachel Wyllie, CEO of CRF Health, who will become the Executive Chairman of the combined company. “The complementary nature of the two businesses provides us with the platform and scale for future growth in our dynamic markets, while ensuring our customers have more access to the latest patient-centric innovations in clinical research.”

Jean-Pierre Conte, Chairman and Managing Director at Genstar Capital, added, “Bringing CRF and Bracket together will create a world-class healthcare technology company supporting clinical trials and will accelerate adoption and growth in eCOA, eConsent, patient engagement, rater training and trial supply management solutions. We look forward to working with the outstanding leaders at both organizations. This notable event in pharmaceutical services is another example of Genstar’s private equity strategy of driving change at our portfolio companies to create high-growth and extremely valuable companies. Healthcare is an important sector for Genstar and we continue to identify great opportunities to apply our growth model to build great companies.”

Philip Russmeyer, Partner at Vitruvian Partners, commented, “We are delighted to support the combination of Bracket and CRF to further accelerate, and build upon, the excellent advances that our partnership with the strong management team at CRF has produced over the past years.”

The transaction is expected to be completed by the end of 2018 and is subject to customary closing and regulatory approvals.

Jefferies International Limited served as exclusive financial adviser and Dickson Minto as legal adviser to CRF.  Ropes & Gray LLP served as legal adviser to Genstar Capital.

About Bracket

Bracket (www.bracketglobal.com) is a technology company that accelerates clinical research and improves the experience of patients accessing potentially life-changing therapies. Our solutions, combined with deep scientific and clinical insight, link engaged patients to researchers, provide faster, more reliable decision making, and help provide longer, healthier and more productive lives for our families and communities around the globe. Bracket has over 800 employees and delivers services in more than 90 countries to a diverse base of global customers, including 15 of the top 20 biopharma companies.

About CRF Health

CRF Health is the leading provider of patient-centered eSource technology solutions for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® platform consistently demonstrates the industry’s highest data accuracy, patient and site compliance, and patient retention. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent®, an electronic solution for collecting and managing informed consent in clinical trials. CRF Health’s eSource solutions improve trial engagement by making the patient the center of the clinical trial process.

About Genstar Capital

Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high quality companies for more than 25 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar manages funds with total capital commitments of approximately $10 billion and targets investments focussed on targeted segments of the healthcare, financial services, software, and industrial technology industries.

About Vitruvian Partners

Vitruvian is a European growth-focused investment firm specialised in ‘dynamic situations’, where companies undergo growth and change typically driven by technology. Vitruvian helps portfolio companies scale their operations by providing an operational support system and assistance with strategic initiatives including acquisitions. Other notable investments to date include global market leaders in their field such as Just Eat, FarFetch, Skyscanner, EasyPark, Snow Software, Trustpilot, Voxbone, Callcredit, Ebury and others. The €2.4bn Vitruvian Investment Partnership III (“VIP III”) is among the largest pools of capital in Europe supporting innovative and higher growth companies. Vitruvian has backed 30 companies in its first two funds and has assets under management of c. €5 billion, operating out of offices in London, Munich, Stockholm, Luxembourg and San Francisco. More information can be found at: www.vitruvianpartners.com

###

MEDIA INQUIRIES:

Contact: Chris Tofalli
Chris Tofalli Public Relations
914-834-4334